Prostate cancer patients with BRCA2 mutation face poor survivalBMJ 2008; 337 doi: https://doi.org/10.1136/bmj.a705 (Published 10 July 2008) Cite this as: BMJ 2008;337:a705
- Roger Dobson
Survival among patients with prostate cancer who have a mutation of the BRCA2 gene is poor, with only one in four known carriers of the mutation alive 10 years after diagnosis.
The median survival from diagnosis among men with the mutation is four years, finds a new study, whose authors say it may be important to develop chemotherapies targeted at such men (British Journal of Cancer doi: 10.1038/sj.bjc.6604453).
“The survival …